Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Down 1% – What’s Next?

Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) fell 1% during trading on Friday . The stock traded as low as $0.50 and last traded at $0.50. 2,161,888 shares traded hands during trading, an increase of 100% from the average session volume of 1,082,880 shares. The stock had previously closed at $0.51.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. HC Wainwright boosted their price objective on shares of Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. D. Boral Capital dropped their target price on shares of Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th.

Lineage Cell Therapeutics Price Performance

The stock has a market capitalization of $110.21 million, a P/E ratio of -4.17 and a beta of 1.16.

Hedge Funds Weigh In On Lineage Cell Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of LCTX. SG Americas Securities LLC bought a new position in Lineage Cell Therapeutics during the third quarter valued at about $46,000. XTX Topco Ltd acquired a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter worth approximately $61,000. GSA Capital Partners LLP bought a new stake in shares of Lineage Cell Therapeutics during the third quarter valued at approximately $84,000. Rhumbline Advisers raised its stake in shares of Lineage Cell Therapeutics by 15.1% in the second quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock valued at $132,000 after purchasing an additional 17,411 shares in the last quarter. Finally, Barclays PLC lifted its position in Lineage Cell Therapeutics by 311.3% in the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after purchasing an additional 159,924 shares during the period. Institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.